AstraZeneca Expects Coronavirus Vaccine Trial Results by End of Year

AstraZeneca (NASDAQ: AZN) said Thursday that it remains on track to be able to report data from the late-stage trials of its COVID-19 vaccine candidate despite a pause that lasted most of September and October, maintaining the company among the leaders in the race for a coronavirus vaccine.

AstraZeneca's phase 3 trials for AZD1222 were paused on Sept. 6 due to the unexplained illness of a trial participant, and didn't resume until Oct. 23. At that time, the company said it still expected results this year, and management confirmed that outlook during its third-quarter earnings conference call Thursday. It also said that AstraZeneca should be able to supply "hundreds of millions" of doses of AZD1222 in January, assuming the trials are successful and the vaccine receives regulatory approval by the end of the year.

Image source: Getty Images.

Continue reading

Source Fool.com